Brief Rapid Communication
Background. Platelet-associated epidermal growth factor (EGF) and transforming growth factor-P (TGF-,B) can augment synthesis of plasminogen activator inhibitor type 1 (PAI-1). Accordingly, exacerbation of atherogenesis may accompany release of platelet-associated growth factors (or mitogens) occurring in association with occult, repetitive thrombosis and thrombolysis. In the Helsinki primary prevention trial, gemfibrozil decreased coronary events but did so essentially only in initially hypertriglyceridemic subjects. Such subjects are known to exhibit high concentrations of PAI-1 in plasma.
Methods and Results. To determine whether pharmacological concentrations of gemfibrozil directly affect PAI-1 synthesis, we characterized its effects on a human hepatoma cell line (Hep G2) in vitro. Gemfibrozil decreased basal PAI-1 secretion by 43% and attenuated the augmentation of PAI-1 synthesis over 24 hours induced by EGF and TGF-f3 by 37% and 39%, without altering overall protein synthesis. Furthermore, it blocked the EGF and TGF-,B-induced increases in PAIT1 mRNA over 6 hours by 65% and 601%. Increases in plasma PAI activity induced by infusion of purified growth factors or by autologous platelet lysates in rabbits were inhibited by gemfibrozil by more than 50%.
Conclusions. 8 Furthermore, activation of platelets, degranulation, and release of platelet-associated growth factors in vivo can increase PAI-1 synthesis.8.9 In the Helsinki primary prevention trial,10-13 both coronary events and mortality were decreased by gemfibrozil, especially in subjects with initially low high-density lipoprotein (HDL) cholesterol and hypertriglyceridemia.12 It is known that high concentrations of PAI-1 in plasma are associated with high concentrations of triglycerides, perhaps because both are influenced by hyperinsulinemia.14-16 We have shown that insulin and insulin-like growth factor stimulate production of PAI-1 in Hep G2 cells, suggesting that the liver may be one source of the insulin-induced increases in plasma PAI-1.17 Thus, it is not surprising that gemfibrozil, known to lower plasma triglycerides, has been found to lower plasma PAI-118 in survivors of acute myocardial infarction. Because reduction of mortality in the Helsinki study was most striking in patients in whom plasma PAI-1 activity was likely to have been particularly elevated in association with hypertriglyceridemia, the favorable effects of gemfibrozil may have been attributable to reduction of PAI-1 and potentiation of fibrinolysis with consequently diminished thrombosis and atherogenesis. Accordingly, we considered the possibility that gemfibrozil may decrease PAI-1 in a fashion independent of its lipid-lowering effects and that such direct effects may have contributed to benefit. In this study, we characterized direct effects of gemfibrozil on PAI-1 synthesis and mRNA levels independent of changes in concentrations of lipids in the media in Hep G2 cells in vitro and on PAI-1 synthesis in vivo in normal, normolipidemic animals in response to plateletassociated growth factors and to autologous platelet lysates.
Methods

Cell Culture and Labeling Procedures
Although diverse cell types produce PAI-1, hepatocytes have been implicated as one primary source of plasma PAI-. 19 In this study, Hep G2 cells, used as a model system, were cultured as previously described. [35S]methionine, washed twice with serum-free medium, and incubated for specified intervals in 1.0 ml serumfree medium with or without gemfibrozil. For assay of PAI-1 synthesis, cells that had been cultured to confluency were preincubated for up to 9 hours in 1.0 ml serum-free medium containing gemfibrozil, washed three times with labeling medium, and incubated for 20 minutes in labeling medium containing [ Assay of PAl-1 Antigen and Activity PAI-1 antigen in conditioned media was assayed as previously described with an enzyme-linked immunosorbent assay (ELISA)21; PAI-1 activity in rabbit plasma was assayed spectrophotometrically22 with a kinetic, chromogenic substrate assay.23
Northern Blots A 1.1-kb PAI-1 cDNA probe was generated by digestion of PAI-1 cDNA (kindly provided by Dr kg, 2.5 ml/kg) over 2 hours beginning 1 hour before infusion of purified platelet-associated growth factors or autologous platelet lysates prepared as previously described.2 In some, an additional infusion (8.75-20 mg/ kg) was implemented over 2 hours beginning 2 hours after the initial infusion of growth factors or lysates. Some animals were given intravenous cycloheximide (2 mg/kg body wt) in PBS (2.5 ml/kg) over 10 minutes I hour before infusion of growth factors or lysates. In some, a second injection (1 mg/kg) of cycloheximide was given 2 hours after the infusion. Controls were given infusion of saline (2.5 ml/kg).
To characterize effects on protein and PAI-1 synthesis, [355] methionine (80 gCi/kg) was administered intravenously 2 hours 40 minutes after infusion of gemfibrozil (8.75 mg/kg), cycloheximide (2 mg/kg), or saline. Twenty minutes later, 1-g samples of tissues of interest were obtained, minced thoroughly, and homogenized with a Polytron PTA-7. Trichloroacetic acid precipitable radioactivity was assayed as described previously.28 Pretreatment of rabbits with cycloheximide for 3 hours reduced protein synthesis (incorporation of [i5Slmethio-nine into trichloroacetic acid-insoluble protein in liver and diverse tissues) by 84% (n-3). In contrast, gemfibrozil (8.75 mg/kg) did not affect incorporation (n-3). Results were expressed as mean±SD.
Results
Elaboration of PAI-1 in Hep G2 Cells
Cultured Hep G2 cells exhibited basal secretion rates of PAI-I (Figure 1 ) of 82±12 ng/105 cells over 24 hours. Exposure of cells to epidermal (EGF) or transforming growth factor-fl (TGF-,f) increased PAI-1 secretion as previously observed2,3 by 2.8-fold and 6.1-fold over 4 hours and 4.1 -fold and 8.5 -fold over 24 hours. Gemfibrozil attenuated basal PAI-1 secretion by 43i10%, and EGF and TGF-fl induced increases by 37±12% and 39±2% over 24 hours without altering overall protein synthesis (Figure 1 ). The increase of PAI-1 in the media accelerated when matrix had become relatively saturated. 20 To determine whether inhibition of PAI-I synthesis was secondary to changes in steady-state concentration of PAI-1 mRNA induced by gemfibrozil, Northern blots were performed. Within 6 hours after addition of gemfibrozil, PAI-1 mRNA had decreased significantly (Figure 2) , with no change in coagulation factor X or GAP mRNA levels. Gemfibrozil blocked the 3.3±0.5-fold EGF-induced increase of PAI-1 mRNA by 65+2% and the 7.8±2.3-fold TGF-P-induced increase by 60±8%.
The rapid decrease in PAI-1 mRNA in cells exposed to gemfibrozil could reflect an increased rate of degradation of PAI-1 transcripts. However mg/kg 2 hours after EGF (A, n=3), and 20 mg/kg 1 hour before EGFplus 20 mg/kg 2 hours after EGF (,, n=4) attenuated the increase in a dose-dependent fashion. Platelet lysates increased PAI activity in plasma as well (panel B). Thus, in animals given platelet lysates (2.8x108/kg) at time 0, PAI activity increased, with a peak at 4 hours (-, n=4). Gemfibrozil 20 mg/kg 1 hour before infusion plus 20 mg/kg 2 hours after infusion ofplatelets (-, n=4) attenuated the increase. Animals given EGF 5 g/kg at time 0 (e, n=4) exhibited an increase in PAI activity. Cycloheximide 2 mg/kg given 1 hour before EGF (i, n=4) or 2 mg/kg 1 hour before EGF and 1 mg/kg 2 hours after EGF (A, n=3) attenuated the increase (panel C).
TGF-p5 was not altered by gemfibrozil. Thus, the rapid decrease in steady-state concentrations of PAI-1 mRNA induced by gemfibrozil reflected decreased synthesis.
To determine whether the rate of release of PAI-1 protein from cells, independent of synthesis per se, was altered by gemfibrozil, cells were incubated for 16 hours with ["S]methionine, washed extensively with serumfree medium, and exposed to unlabeled media in the presence or absence of gemfibrozil for up to 24 hours. Figure  4A) , with no further attenuation with higher concentrations of gemfibrozil (40 mg/kg). Similar effects were noted with platelet lysates ( Figure 4B) , with attenuation of increments in PAI-1 after 4 and 5 hours by 33% and 53%. Cycloheximide (1 hour before and 2 hours after infusion of EGF) attenuated the PAI-1 increase over 2 hours by 95% (2 mg/kg) and 98% (3 mg/kg) ( Figure  4C ). No 
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